Research
Hormonal
FGF19 increases metabolic rate and improves glucose homeostasis by increasing fatty acid oxidation and decreasing liver triglycerides, mediated by the suppression of Acetyl CoA Carboxylase 2 (ACC2) and increased leptin receptor expression in the liver.
FGF19 works by telling the liver to burn more fat. It does this by turning off ACC2 (a gatekeeper for fat storage) and turning up leptin receptors (sensitivity to the fat-regulating hormone leptin).
GoodSupportsHIGH confidence
We also found that FGF19 acutely increased liver expression of the leptin receptor (1.8-fold; P < 0.05) and decreased the expression of acetyl coenzyme A carboxylase 2 (0.6-fold; P < 0.05). The gene expression changes were consistent with the experimentally determined increase in fat oxidation and decrease in liver triglycerides.
Why this rating
Supported by gene expression data (RT-PCR, Affymetrix arrays) and metabolic assays (RQ, FFA levels).
Source
Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient Diabetes
Ling Fu et al. · Endocrinology · 2004
DOI 10.1210/en.2003-1671
mechanism_onlyCited 565×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Administration of recombinant human Fibroblast Growth Factor 19 (FGF19) increases metabolic rate and reverses diet-induced and leptin-deficient diabetes in mice without reducing food intake.Good
- Brown Adipose Tissue (BAT) activation is not essential for FGF19 to increase metabolic rate and reverse obesity/diabetes, as FGF19 remains effective in mice with diminished BAT (UCP-DTA mice).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →